• 1
    Furlan M, Robles R, Galbusera M, Remuzzi A, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lammle B. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. N Engl J Med 1998; 339: 157884.
  • 2
    Tsai H-M, Lian EC. Antibodies to von willibrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 158594.
  • 3
    Wiestner A, Hearn J, Asch AS, Michelis AM, Zeller JA, Peerschke EIB, Weksler BB, Schechter AP. Rituximab in the treatment of acquired factor VIII inhibitors. Blood 2002; 100: 34268.
  • 4
    Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001; 98: 9527.
  • 5
    Chemnitz J, Draube A, Scheild C, Staib P, Schulz A, Diehl V, Sohngen D. Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab. Am J Hem 2002; 71: 1058.
  • 6
    Zheng X, Pallera AM, Goodnough LT, Sadler JE, Blinder ME. Remisison of chronic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. Ann Int Med 2003; 38: 1058.
  • 7
    Gutterman LA, Klostr B, Tsai H-M. Rituximab therapy for refractory thrombotic thrombocytopenic purpura. Blood Cells Mol Dis 2002; 28: 38591.